Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study

(2016) Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study. Pharmacopsychiatry.

Full text not available from this repository.

Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Introduction: Although the pathogenesis of symptoms of schizophrenia is largely unknown, a variety of neurotransmitters are implicated, including serotonin and norepinephrine. Here we investigate the effectiveness of duloxetine as a serotonin-norepinephrine inhibitor in the treatment of negative symptoms. Methods: We performed a double-blind clinical trial on 64 patients with stable schizophrenia and no prominent symptoms of depression. Patients received risperidone (up to 6 mg/day) plus either duloxetine (60 mg/day) or placebo. Psychotic symptoms were assessed by the Positive and Negative Syndrome Scale (PANSS) at the onset of the trial, and at 2, 4, 6 and 8 weeks of therapy. Results: Compared to the placebo group, the duloxetine group showed significantly higher improvement in negative symptoms (p<0.001), PANSS total (p<0.001), and the general psychopathology subscale scores (p=0.001), but no significant difference in positive symptoms (p=0.13). The side effect profiles of the 2 treatment regimens were not significantly different. Discussion: Duloxetine adjuvant to risperidone seems to be a tolerable and efficacious treatment for primary negative symptoms of schizophrenia. © 2016 Georg Thieme Verlag KG Stuttgart New York.

Item Type: Article
Keywords: duloxetine; fluphenazine; haloperidol; olanzapine; placebo; risperidone; analgesic agent; duloxetine; neuroleptic agent; risperidone, absence of side effects; adult; Article; controlled study; depression; disease duration; double blind procedure; drug efficacy; female; Hamilton Depression Rating Scale; human; major clinical study; male; negative syndrome; Positive and Negative Syndrome Scale; priority journal; randomized controlled trial; schizophrenia; treatment outcome; adolescent; combination drug therapy; complication; follow up; middle aged; nonparametric test; psychological rating scale; psychology; Psychotic Disorders; schizophrenia; young adult, Adolescent; Adult; Analgesics; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Statistics, Nonparametric; Treatment Outcome; Young Adult
Page Range: pp. 162-169
Journal or Publication Title: Pharmacopsychiatry
Volume: 49
Number: 4
Publisher: Georg Thieme Verlag
Identification Number: 10.1055/s-0042-101557
ISSN: 01763679
Depositing User: مهندس جمال محمودپور
URI: http://eprints.muk.ac.ir/id/eprint/540

Actions (login required)

View Item View Item